7th Annual Achieving Quality & Process Excellence in the Pharmaceutical Industry

Fleming Europe24 - 25 May 2011, Barcelona, Spain.
What are the new approaches to quality to achieve world-class manufacturing performance? How can you successfully introduce innovation and continual improvement into manufacturing?

Continuing pressures on life sciences manufacturing, from increased competition to regulatory requirements, are forcing organizations to achieve tighter operating efficiencies, while improving their ability to satisfy quality compliance standards.

Leading Pharma companies are now looking to Lean Manufacturing and Six Sigma principles to help them boost operational efficiency and improve quality. Explore the importance of six sigma in process validation and how to successfully apply Lean approach in Quality Assurance to simplify the processes.

Discuss with leading experts, how to build a sustainable quality culture during the times of change. Understand how to apply QbD tools during method development phase to achieve robust and reliable analytical procedures. Gain critical insights & first-hand experience how to incorporate risk management thinking and practices across the entire organization.

This event will bring together senior industry quality & operational excellence experts from the Pharmaceutical industry presenting real life case studies as well as a lot of networking sessions and discussions.

Key speakers:

  • Head of Quality Control, Sanofi Aventis, Germany
  • Senior Vice President Quality Assurance, Glenmark Pharmaceuticals, India
  • Head Operational Excellence & Lean, AstraZeneca, Sweden
  • Director Turbuhaler, AstraZeneca, Sweden
  • Quality Assurance Projects, Abbott, Italy
  • Head of Processes & Product Quality, Belupo, Croatia
  • More speakers to be announced

Key topics:

  • Explore Process Innovations for Operational Excellence
  • Enhance six sigma strategies to control costs, improve productivity and maintain compliance – how to integrate Quality & Operational Efficiency
  • Understand, how to link quality to performance
  • Reveal new approaches & tools for facilitating continuous improvement - building a sustainable quality culture and getting the right thinking across the entire organization
  • Maximize the benefits of QbD and Process understanding - best practices in QbD & PAT
  • Embrace Quality Risk Management - from theory to practice
  • Deployment of quality management for biologics - new challenges in aseptic processing of biologics
  • Understand new regulatory aspects of modern quality management and being prepared for the inspection

PLUS 3 Interactive Workshops:

  • Achieving efficiency in Quality Control
  • Application of Lean approach to Quality Assurance
  • Quality Risk Management - the new paradigm

Who should attend:
Vice Presidents, Heads, Directors, Senior Managers and Managers of: Quality Management, Quality Assurance, Quality Operations, Quality Control, Quality Systems, Regulatory Affairs, GMP Compliance, Quality by Design, PAT, Lean/Six Sigma, Lean Manufacturing, API manufacturing, Technical operations, Contract Manufacturing, Operational Excellence, Business Process Excellence, Operations, Production, Manufacturing, Supply Chain, Quality Risk Management, Qualified Person, Right First Time leaders.

For further information and registration, please visit:
http://flemingeurope.com/pharmaceuticals-conferences/europe/7th-annual-achieving-quality-process-excellence-in-the-pharmaceutical-industry

About Fleming Europe conferences
Fleming Europe conferences are events linking business with intelligence. Carefully designed to provide key strategic business information and the best networking opportunities for the participants, our B2B conferences are highly interactive. Number of delegates from specialized industry sectors - brought together by Fleming Europe - become part of a premium community discussing the questions of the day and enjoying the value of a five star event.

Most Popular Now

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

Time-restricted eating reshapes gene expression th…

Numerous studies have shown health benefits of time-restricted eating including increase in life span in laboratory studies, making practices like intermittent fasting a ...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...

500,000 missed out on blood pressure lowering drug…

Nearly half a million people missed out on starting medication to lower their blood pressure during the COVID-19 pandemic, according to research supported by the British ...